NYSE$EVH
Evolent Health Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Evolent Health reported revenue increase driven by growth in Clinical Solutions and Evolent Health Services, but net loss was recorded due to higher expenses.
Evolent Health announced its Q4 2022 results, revealing a 54.0% increase in revenue to $382.4 million compared to the same period last year. However, the company reported a net loss of $11.3 million, with an adjusted EBITDA of $32.3 million.
- Revenue increased by 54.0% to $382.4 million compared to Q4 2021.
- Net loss attributable to common shareholders was $11.3 million, resulting in a net loss margin of (3.0)%.
- Adjusted EBITDA reached $32.3 million, with an adjusted EBITDA margin of 8.4%.
- Total Lives on Platform reached 20.6 million, including 2.2 million Evolent Health Services Lives and 18.5 million Clinical Solutions Lives.
Headline financials
Revenue & EPS history
Evolent Health · Revenue · Quarterly
$382M
Revenue by segment
Evolent Health · $92.7M total across 3 segments · Q3 2023
- Cases$37.4M—40.3%
- Performance Suite$32.8M—35.4%
- Administrative Services$22.5M—24.3%
Forward guidance
For the first quarter of 2023, Evolent Health expects revenue to be in the range of $420 million to $440 million and adjusted EBITDA to be in the range of $45 million to $50 million. For the full year 2023, the company anticipates revenue between $1.92 billion and $1.96 billion, with adjusted EBITDA ranging from $180 million to $200 million.
Tailwinds
- Revenue for Q1 2023 is expected to be between $420 million and $440 million.
- Adjusted EBITDA for Q1 2023 is projected to be in the range of $45 million to $50 million.
- Full year 2023 revenue is anticipated to be between $1.92 billion and $1.96 billion.
- Adjusted EBITDA for the full year 2023 is expected to range from $180 million to $200 million.
- Cash deployed for software development is expected to be in the range of $35 million - $40 million for the year ended December 31, 2023.
Headwinds
- The company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort.
- Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to acquisitions and other events.
- Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations.
- The exact amount of these adjustments are not currently determinable but may be significant.
- Actual results may differ materially due to factors set forth in the company's filings with the SEC.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+2.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
-1.9%
Avg return
30 days after
65%
32 / 49 earnings
Positive
+29.2%
Q2 2024
Best reaction
-46.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.5% | +8.6% | +9.9% | |
| Q4 2025 | +25.0% | +39.8% | -13.7% | |
| Q3 2025 | -17.5% | -25.8% | -34.3% | |
| Q1 2025 | -16.2% | -17.1% | -22.7% | |
| Q4 2024 | -2.6% | -11.8% | -10.6% | |
| Q3 2024 | -46.1% | -41.7% | -55.0% | |
| Q2 2024 | +29.2% | +28.5% | +49.3% | |
| Q1 2024 | -10.3% | -12.5% | -13.9% | |
| Q4 2023 | +13.8% | +14.1% | +8.3% | |
| Q3 2023 | +13.5% | +18.4% | +20.4% | |
| Q2 2023 | -7.5% | -4.6% | -14.2% | |
| Q1 2023 | -4.3% | -0.9% | -11.4% | |
| Q4 2022 | +9.1% | +9.0% | -4.4% | |
| Q3 2022 | -10.8% | -22.4% | -1.2% | |
| Q2 2022 | +4.9% | +2.7% | +6.2% | |
| Q1 2022 | +0.9% | -8.5% | +4.0% | |
| Q4 2021 | +13.9% | +16.4% | +34.8% | |
| Q3 2021 | +3.4% | +0.3% | -10.4% | |
| Q2 2021 | +3.5% | +2.9% | +13.5% | |
| Q1 2021 | +8.2% | +11.7% | +5.2% | |
| Q4 2020 | -3.1% | -6.9% | -0.9% | |
| Q3 2020 | +6.9% | +15.3% | +41.0% | |
| Q2 2020 | +8.3% | +8.8% | +13.7% | |
| Q1 2020 | +12.6% | +11.4% | -1.6% | |
| Q4 2019 | -13.7% | -18.2% | -48.0% | |
| Q3 2019 | +16.3% | +29.7% | -14.4% | |
| Q2 2019 | +9.3% | +17.2% | +13.4% | |
| Q1 2019 | -1.3% | +0.9% | -34.6% | |
| Q4 2018 | -3.5% | -8.8% | -14.2% | |
| Q3 2018 | +14.5% | +10.8% | -8.5% | |
| Q2 2018 | +1.4% | +5.0% | +17.2% | |
| Q1 2018 | +8.4% | +12.8% | +36.4% | |
| Q4 2017 | +1.0% | +5.5% | -1.7% | |
| Q3 2017 | -13.4% | -27.5% | -16.0% | |
| Q2 2017 | -17.6% | -23.7% | -25.9% | |
| Q1 2017 | +3.3% | +5.0% | +14.2% | |
| Q4 2016 | +5.7% | +1.2% | +8.0% | |
| Q3 2016 | -3.1% | -9.7% | -13.9% | |
| Q2 2016 | +3.8% | +9.6% | +3.1% | |
| Q1 2015 | +0.7% | — | — | |
| Q1 2016 | +14.5% | — | — | |
| Q4 2013 | +3.9% | — | — | |
| Q1 2014 | +3.9% | — | — | |
| Q2 2015 | +3.9% | — | — | |
| Q4 2015 | +14.6% | — | — | |
| Q3 2014 | +12.0% | — | — | |
| Q3 2015 | +11.8% | — | — | |
| Q2 2014 | -8.5% | — | — | |
| Q4 2014 | -8.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro